Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) Cost of Revenue (2023 - 2025)

Historic Cost of Revenue for Fennec Pharmaceuticals (FENC) over the last 3 years, with Q3 2025 value amounting to $5.2 million.

  • Fennec Pharmaceuticals' Cost of Revenue rose 1323.63% to $5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.5 million, marking a year-over-year decrease of 1032.7%. This contributed to the annual value of $18.4 million for FY2024, which is 5199.21% up from last year.
  • Per Fennec Pharmaceuticals' latest filing, its Cost of Revenue stood at $5.2 million for Q3 2025, which was up 1323.63% from $4.4 million recorded in Q2 2025.
  • In the past 5 years, Fennec Pharmaceuticals' Cost of Revenue ranged from a high of $5.2 million in Q3 2025 and a low of $2.3 million during Q2 2023
  • For the 3-year period, Fennec Pharmaceuticals' Cost of Revenue averaged around $3.9 million, with its median value being $3.9 million (2024).
  • Its Cost of Revenue has fluctuated over the past 5 years, first surged by 10580.8% in 2024, then tumbled by 4342.48% in 2025.
  • Fennec Pharmaceuticals' Cost of Revenue (Quarter) stood at $3.9 million in 2023, then grew by 1.96% to $3.9 million in 2024, then surged by 32.1% to $5.2 million in 2025.
  • Its Cost of Revenue was $5.2 million in Q3 2025, compared to $4.4 million in Q2 2025 and $2.9 million in Q1 2025.